223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice

Purpose To identify pre-therapeutic variables associated with overall survival (OS) in patients treated with 223Ra. Methods Data from 45 CRPC patients treated with 223Ra were retrospectively analyzed. All patients who received at least one 223Ra injection were included in the study. Cox proportional hazard regression models were used to estimate hazard ratio's (HR) and to test for association. Results Twenty-one patients (47%) received six 223Ra injections and 24 patients (53%) received one to five 223Ra injections. Median OS since start of 223Ra was 13.0 months (95% confidence interval (CI) 8.2–17.8). Patients who completed 223Ra therapy had a median OS of 19.7 months (95% CI 14.9–24.6), while patients who received one to five 223Ra injections had a median OS of 5.9 months (95% CI 3.8–8.1; P

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2BdI1xX
via IFTTT